Search

Your search keyword '"W135 meningococcal disease"' showing total 2 results
Start Over Descriptor "W135 meningococcal disease"
2 results on '"W135 meningococcal disease"'

1. Meningococcal disease: Risk for international travellers and vaccine strategies.

Author

Wilder-Smith, Annelies

Abstract

Summary: International travel and migration facilitate the rapid intercontinental spread of meningococcal disease. Serogroup A and, less so serogroup C, have been responsible for epidemics in the past (mainly in Africa). In recent years, W135 has emerged (first in Saudi Arabia, then in West Africa) as a serogroup that requires attention. Serogroups X and Y are infrequent, but associated with slowly rising trends. There are significant variations in the incidence of meningococcal disease and the distribution of serogroups responsible for meningococcal disease, both geographically and with time. Vaccine strategies need to address this variation, and broad coverage against all serogroups for which vaccines are currently available should be offered to travellers. Tetravalent polysaccharide meningococcal vaccines are limited by their poor immunogenicity in small infants and by the lack of long-term protection. In contrast, the novel tetravalent conjugate vaccine that is currently only available in North America is immunogenic in young infants, induces long-term protection and reduces nasopharyngeal carriage. The tetravalent conjugate meningococcal vaccine will be a leap forward in the control of meningococcal epidemics in affected countries. It will also boost the uptake of meningococcal vaccines in travellers because the duration of protection is longer and it eliminates the problem of immune hyporesponsiveness of serogroup C with repeated dosing. Current vaccine recommendations are to vaccinate all Hajj pilgrims, all travellers to areas with current outbreaks, travellers to the SubSaharan meningitis belt, and individuals with certain medical conditions. [Copyright &y& Elsevier]

Published
2008
Full Text
View/download PDF

2. Bacterial agents causing meningitis during 2013-2014 in Turkey: A multi-center hospital-based prospective surveillance study

Author

Yasemin Ozsurekci, Zafer Kurugöl, Hasan Tezer, Fatih Yilmaz, Ünal Uluca, Rengin Şiraneci, Diyar Tamburaci, Ümit Çelik, Gulnar Sensoy, Ahu Kara, Mehmet Ceyhan, Yildiz Camcioglu, Nilden Tuygun, Nezahat Gürler, Aslınur Özkaya Parlakay, Metehan Ozen, Nuran Salman, Ener Cagri Dinleyici, Necdet Kuyucu, Melda Celik, Eda Karadag Oncel, Sefika Elmas Bozdemir, Aybüke Akaslan, Melike Emiroglu, Emre Alhan, Fatmanur Öz, Ümmühan Çay, Fatih Akin, Adem Karbuz, Nevin Hatipoğlu, Solmaz Celebi, Nurşen Belet, Tolga İnce, İlker Devrim, Enes Coskun, Mustafa Hacimustafaoglu, OMÜ, Ege Üniversitesi, Çukurova Üniversitesi, İç Hastalıkları, Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Enfeksiyon Hastalıkları Anabilim Dalı., Hacımustafaoğlu, Mustafa, Çelebi, Solmaz, and Selçuk Üniversitesi

Subjects
Male, Pediatrics, Turkey, Bacterial meningitis, W135 meningococcal disease, Neisseria meningitidis, 0302 clinical medicine, Bacterium, Observational study, Epidemiology, Pathology, Immunology and Allergy, 030212 general & internal medicine, Child, Children, Vaccines, Epidemiological monitoring, Incidence, Hospital based, Classification, Research Papers, Multicenter study, Polymerase chain reaction, Hospitalization, Clinical trial, ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS, Neisseria-meningitidis, hospital surveillance, Female, epidemiology, InformationSystems_MISCELLANEOUS, Meningitis, Human, Adult, medicine.medical_specialty, Surveillance study, Adolescent, Child, preschool, Fever, Immunology, Microbiology, Article, 03 medical and health sciences, 030225 pediatrics, medicine, Humans, Prospective study, Intensive care medicine, Meningitis, bacterial, Pharmacology, etiologic agents, Bacteria, business.industry, ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS, Infant, medicine.disease, Nonhuman, Mycoplasma pneumoniae, ComputingMethodologies_PATTERNRECOGNITION, Meningococcosis, Serotype, Neisseria Meningitidis, Preschool child, Isolation and purification, Biotechnology & Applied Microbiology, Immunization, School child, business, Prospective studies, Meta analysis
Abstract

WOS: 000388736900040, PubMed: 27454468, This is an observational epidemiological study to describe causes of bacterial meningitis among persons between 1 month and 18 y of age who are hospitalized with suspected bacterial meningitis in 7 Turkish regions. covering 32% of the entire population of Turkey. We present here the results from 2013 and 2014. A clinical case with meningitis was defined according to followings: any sign of meningitis including fever, vomiting, headache, and meningeal irritation in children above one year of age and fever without any documented source, impaired consciousness, prostration and seizures in those < 1 y of age. Single tube multiplex PCR assay was performed for the simultaneous identification of bacterial agents. The specific gene targets were ctrA, bex, and ply for N. meningitidis, Hib, and S. pneumoniae, respectively. PCR positive samples were recorded as laboratory-confirmed acute bacterial meningitis. A total of 665 children were hospitalized for suspected acute meningitis. The annual incidences of acute laboratory-confirmed bacterial meningitis were 0.3 cases / 100,000 population in 2013 and 0.9 cases/100,000 in 2014. Of the 94 diagnosed cases of bacterial meningitis by PCR, 85 (90.4%) were meningococcal and 9 (9.6%) were pneumococcal. Hib was not detected in any of the patients. Among meningococcal meningitis, cases of serogroup Y, A, B and W-135 were 2.4% (n = 2), 3.5% (n = 3), 32.9% (n = 28), and 42.4% (n = 36). No serogroup C was detected among meningococcal cases. Successful vaccination policies for protection from bacterial meningitis are dependent on accurate determination of the etiology of bacterial meningitis. Additionally, the epidemiology of meningococcal disease is dynamic and close monitoring of serogroup distribution is comprehensively needed to assess the benefit of adding meningococcal vaccines to the routine immunization program., GlaxoSmithKline Biologicals SAGlaxoSmithKline, Funding for this study was provided by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of this manuscript for factual accuracy but the authors are solely responsible for final content and interpretation. The authors received no financial support or other form of compensation related to the development of the manuscript.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results